Journal of Research in Pharmacy Practice最新文献

筛选
英文 中文
The Effect of Intravenous Lipid Emulsion in Tricyclic Antidepressant Poisoning: A Systematic Review. 静脉注射脂质乳剂治疗三环类抗抑郁药物中毒的疗效综述。
IF 0.7
Journal of Research in Pharmacy Practice Pub Date : 2026-10-17 eCollection Date: 2026-01-01 DOI: 10.4103/jrpp.jrpp_55_26
Aliasghar Sajedi, Arman Otroshi, Neda Arabizadeh, Abolfazl Taheri, Rokhsareh Meamar, Marzieh Khalilzadeh, Ali Mohammad Sabzghabaee, Nastaran Eizadi-Mood
{"title":"The Effect of Intravenous Lipid Emulsion in Tricyclic Antidepressant Poisoning: A Systematic Review.","authors":"Aliasghar Sajedi, Arman Otroshi, Neda Arabizadeh, Abolfazl Taheri, Rokhsareh Meamar, Marzieh Khalilzadeh, Ali Mohammad Sabzghabaee, Nastaran Eizadi-Mood","doi":"10.4103/jrpp.jrpp_55_26","DOIUrl":"https://doi.org/10.4103/jrpp.jrpp_55_26","url":null,"abstract":"<p><p>Tricyclic antidepressant (TCA) poisoning may cause severe hypotension, QRS complex prolongation, arrhythmias, seizures, and cardiac arrest. Intravenous lipid emulsion (ILE) has been proposed as an adjunctive rescue treatment, but its role remains uncertain. We conducted a Preferred Reporting Items for Systematic Reviews and Meta-Analyses-guided systematic review without meta-analysis to evaluate clinical outcomes and safety of ILE in adult patients with TCA poisoning. PubMed/MEDLINE, Embase, Scopus, Web of Science, the Cochrane Library, Google Scholar, Persian-language databases, and gray-literature sources were searched through December 2025. Methodological quality was assessed using design-specific Joanna Briggs Institute critical appraisal checklists for case reports and case series. Uncontrolled case-based evidence was synthesized narratively using descriptive case-level proportions with exact 95% confidence intervals (CIs). Twenty-four studies published between 2009 and 2023 were included: 20 case reports, three case series, and one registry-derived case series, representing 42 cases of uncontrolled case-based evidence. Survival was reported in 41 of 42 cases (97.6%). Survival was reported in all documented arrest cases receiving ILE, although concurrent resuscitative interventions preclude attribution. Hypotension resolved in 14 of 17 cases (82.4%), whereas wide-QRS and arrhythmia resolution occurred in 6 of 14 cases (42.9%) and 4 of 9 cases (44.4%), respectively. Reported adverse events included acute respiratory distress syndrome, hypertriglyceridemia with laboratory interference, and mild liver abnormalities. The evidence was limited by publication bias, lack of comparator groups, selective reporting, concurrent treatments, and absent systematic safety monitoring. Therefore, the findings do not establish the effectiveness or safety of ILE in all TCA poisoning cases. More research is needed before ILE can be supported for routine or first-line use, but ILE may be considered as rescue therapy in selected patients with refractory, life-threatening toxicity alongside standard therapies, with careful monitoring for potential harms.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"15 1","pages":"39"},"PeriodicalIF":0.7,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13759159/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149407437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinically Significant Potential Drug-Drug Interactions among Older Outpatients in Vietnam: Prevalence and Associated Factors in a Cross-sectional Study. 越南老年门诊患者中具有临床意义的潜在药物相互作用:一项横断面研究的患病率和相关因素。
IF 0.7
Journal of Research in Pharmacy Practice Pub Date : 2026-10-03 eCollection Date: 2026-01-01 DOI: 10.4103/jrpp.jrpp_47_26
Nguyen Thi Le Nguyen, Quyen Nguyen Tu Le, Tu Thi Cam Le, Thang Nguyen
{"title":"Clinically Significant Potential Drug-Drug Interactions among Older Outpatients in Vietnam: Prevalence and Associated Factors in a Cross-sectional Study.","authors":"Nguyen Thi Le Nguyen, Quyen Nguyen Tu Le, Tu Thi Cam Le, Thang Nguyen","doi":"10.4103/jrpp.jrpp_47_26","DOIUrl":"10.4103/jrpp.jrpp_47_26","url":null,"abstract":"<p><strong>Objective: </strong>The objective of this study was to estimate the prevalence, severity, mechanisms, actionable high-severity pairs, and associated factors of clinically significant potential drug-drug interactions (DDIs) in older outpatients in Vietnam.</p><p><strong>Methods: </strong>We conducted a descriptive cross-sectional prescription study using systematic random sampling of 909 health-insurance outpatient prescriptions for patients aged 60 years or older at a provincial referral general hospital from April 2021 to April 2022. Potential DDIs were screened with Drugs.com and Medscape (final access: June 30, 2022). Severity ratings were harmonized into three levels; level 1 and level 2 interactions were considered clinically significant. Associated factors were evaluated using multivariable logistic regression.</p><p><strong>Findings: </strong>The mean age was 72.92 ± 8.88 years, and 236 patients (26.0%) were women. Polypharmacy (five or more medicines) occurred in 685 prescriptions (75.4%). Overall, 725 prescriptions (79.8%) contained at least one clinically significant potential DDI, including 84 (9.2%) with at least one level 1 pair. The mean number of clinically significant potential DDIs per prescription was 2.51 ± 2.41. Among 2745 DDI occurrences involving 325 unique pairs, pharmacodynamic mechanisms predominated, especially synergism (1382; 50.4%), and antagonism (527; 19.2%). Polypharmacy was the strongest associated factor (adjusted odds ratio 9.69, 95% confidence interval 6.21-15.11; <i>P</i> < 0.001).</p><p><strong>Conclusion: </strong>Clinically significant potential DDIs were frequent in older Vietnamese outpatients. Combining polypharmacy-based triage with a locally prioritized list of high-severity pairs may help outpatient pharmacists and prescribers convert routine database screening into focused medication-safety actions.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"15 1","pages":"37"},"PeriodicalIF":0.7,"publicationDate":"2026-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13706649/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149269393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of Mirtazapine versus Olanzapine for the Prevention of Chemotherapy-induced Nausea and Vomiting in Highly Emetogenic Chemotherapy: A Double-blind Randomized Crossover Trial. 米氮平与奥氮平预防高致吐性化疗中化疗引起的恶心和呕吐的比较:一项双盲随机交叉试验。
IF 0.7
Journal of Research in Pharmacy Practice Pub Date : 2026-10-03 eCollection Date: 2026-01-01 DOI: 10.4103/jrpp.jrpp_46_26
Fatemeh Farzameh, Ehsan Zaboli, Mohammad Eslamijouybari, Leila Mirzakhani, Mahasty Babaeian Koopaey, Mahmood Moosazadeh, Ebrahim Salehifar
{"title":"Comparison of Mirtazapine versus Olanzapine for the Prevention of Chemotherapy-induced Nausea and Vomiting in Highly Emetogenic Chemotherapy: A Double-blind Randomized Crossover Trial.","authors":"Fatemeh Farzameh, Ehsan Zaboli, Mohammad Eslamijouybari, Leila Mirzakhani, Mahasty Babaeian Koopaey, Mahmood Moosazadeh, Ebrahim Salehifar","doi":"10.4103/jrpp.jrpp_46_26","DOIUrl":"10.4103/jrpp.jrpp_46_26","url":null,"abstract":"<p><strong>Objective: </strong>Chemotherapy-induced nausea and vomiting (CINV) is a distressing complication of chemotherapy. It can compromise treatment adherence and impair patients' quality of life. Despite guideline-recommended drug prophylaxis, many patients still suffer from CINV. This double-blind, randomized crossover clinical trial aims to compare the safety and efficacy of mirtazapine versus olanzapine among patients treated with highly emetogenic chemotherapy (HEC).</p><p><strong>Methods: </strong>Sixty patients undergoing anthracycline-cyclophosphamide (AC) or cisplatin-containing regimen were enrolled. Half of the patients received olanzapine (5 mg/day) plus mirtazapine placebo during cycle 1, followed by mirtazapine (15 mg/day) plus olanzapine placebo in cycle 2 on days 1-4 after chemotherapy. The other half of the patients received the reverse order. Furthermore, all patients received a triplet antiemetic regimen consisting of aprepitant, granisetron, and dexamethasone. The endpoints included rate of complete control (CC), complete response, severity of nausea and vomiting based on NCI-CTCAE, visual analog scale nausea score, and adverse effects across the acute, delayed, and overall phases during the first two cycles of chemotherapy. Patients' quality of life affected by CINV was assessed using the Functional Living Index-Emesis questionnaire.</p><p><strong>Findings: </strong>Overall CC was 56.7% for olanzapine and 53.6% for mirtazapine in cycle 1 (<i>P</i> = 0.813) and 54.5% for mirtazapine and 56.3% for olanzapine in cycle 2 (<i>P</i> = 0.917). The overall CC rate did not differ significantly between olanzapine and mirtazapine (odds ratio = 1.14, 95% confidence interval 0.89-1.35, <i>P</i> = 0.31). Similar findings were observed across all other evaluated outcomes. Sedation was the most common adverse effect. No significant difference was observed between olanzapine and mirtazapine (<i>P</i> = 0.563 for the first cycle and 0.061 for the second cycle).</p><p><strong>Conclusion: </strong>Our findings support that mirtazapine may have comparable outcomes with olanzapine in preventing CINV following HEC.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"15 1","pages":"36"},"PeriodicalIF":0.7,"publicationDate":"2026-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13706655/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149269506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analysis of Opioid Disposal in Hospitalized Patients According to Dosage Form, Dose, Cost, and Admission Type: A Retrospective Study. 根据剂型、剂量、费用和入院类型对住院患者阿片类药物处置的回顾性分析
IF 0.7
Journal of Research in Pharmacy Practice Pub Date : 2026-09-04 eCollection Date: 2026-01-01 DOI: 10.4103/jrpp.jrpp_33_26
Nanami Ogura, Michio Kimura, Eri Anbe, Kayo Ito, Norio Suzuki, Eiseki Usami
{"title":"Analysis of Opioid Disposal in Hospitalized Patients According to Dosage Form, Dose, Cost, and Admission Type: A Retrospective Study.","authors":"Nanami Ogura, Michio Kimura, Eri Anbe, Kayo Ito, Norio Suzuki, Eiseki Usami","doi":"10.4103/jrpp.jrpp_33_26","DOIUrl":"10.4103/jrpp.jrpp_33_26","url":null,"abstract":"<p><strong>Objective: </strong>Opioids are essential for cancer pain management but often require dose or route adjustments, leading to disposal of unused medications. This study investigated opioid disposal by dosage form, dose, economic impact, and admission type.</p><p><strong>Methods: </strong>This retrospective observational study included patients who received oral or transdermal opioids at Ogaki Municipal Hospital between January 2023 and December 2024. Opioid disposal, defined as nonreusable opioids discarded according to narcotics management records, was identified retrospectively. Disposal volume, cost, and reasons for disposal were evaluated. Costs were calculated using official drug prices (April 2025). Associations between admission type and disposal reasons were analyzed using the Chi-square test.</p><p><strong>Findings: </strong>Eighty-eight patients experienced opioid disposal. The total disposal volume was 3022 units, with a total cost of JPY 599,736 (mean: JPY 6815 per patient). Disposal frequently involved low-dose oral opioid formulations, particularly sustained-release oxycodone (5, 10 mg). Pareto analysis showed that the top five drugs accounted for 59.5% of total disposal costs. Disposal reasons differed significantly by admission type (<i>χ</i> <sup>2</sup> = 40.8, df = 4, <i>P</i> < 0.001): death-related disposal occurred only in emergency admissions, whereas planned admissions were more frequently associated with drug changes and represcriptions.</p><p><strong>Conclusion: </strong>Opioid disposal in hospitalized patients occurs frequently, including with low-dose oral formulations. Costs are concentrated in a limited number of drugs and vary by admission type. Optimizing opioid selection and early assessment of administration routes may help reduce unnecessary disposal while maintaining adequate pain control.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"15 1","pages":"34"},"PeriodicalIF":0.7,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13619100/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149074997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Outcomes of Adding Topical Cetirizine to Minoxidil Therapy in Patients with Androgenetic Alopeci. 外用西替利嗪联合米诺地尔治疗雄激素性脱发的临床疗效。
IF 0.7
Journal of Research in Pharmacy Practice Pub Date : 2026-09-04 eCollection Date: 2026-01-01 DOI: 10.4103/jrpp.jrpp_22_26
Fatemeh Mokhtari, Gita Faghihi, Somayeh Maleki, Sayed Mohsen Hosseini, Parvane Sadeghi Dolatabadi
{"title":"Clinical Outcomes of Adding Topical Cetirizine to Minoxidil Therapy in Patients with Androgenetic Alopeci.","authors":"Fatemeh Mokhtari, Gita Faghihi, Somayeh Maleki, Sayed Mohsen Hosseini, Parvane Sadeghi Dolatabadi","doi":"10.4103/jrpp.jrpp_22_26","DOIUrl":"10.4103/jrpp.jrpp_22_26","url":null,"abstract":"<p><strong>Objective: </strong>The objective is to evaluate the efficacy and safety of adding 1% topical cetirizine to 5% topical minoxidil compared with topical minoxidil alone in patients with androgenetic alopecia (AGA).</p><p><strong>Methods: </strong>In this single-blind randomized clinical trial, 62 patients with AGA were allocated to receive either topical minoxidil 5% twice daily (monotherapy group, <i>n</i> = 31) or topical minoxidil 5% twice daily plus topical cetirizine 1% once daily (adjunctive therapy group, <i>n</i> = 31) for 16 weeks. Primary outcomes included changes in hair density and hair diameter scores. Secondary outcomes were global photography score, patient satisfaction, and treatment-related adverse events.</p><p><strong>Findings: </strong>Both groups demonstrated improvement from baseline in hair density and hair diameter scores after 16 weeks of treatment. However, no significant differences were observed between groups in hair density score (0.65 ± 0.61 vs. 0.68 ± 0.60, <i>P</i> = 0.987), hair diameter score (1.29 ± 0.59 vs. 1.39 ± 0.62, <i>P</i> = 0.628), or global photography score (1.00 ± 0.68 vs. 1.06 ± 0.57, <i>P</i> = 0.697). Patient satisfaction was significantly higher in the adjunctive therapy group than in the monotherapy group (1.82 ± 1.07 vs. 1.13 ± 0.85, <i>P</i> = 0.004). Two cases of local irritation were reported in the monotherapy group, whereas no adverse events were reported in the adjunctive therapy group.</p><p><strong>Conclusion: </strong>The addition of 1% topical cetirizine to topical minoxidil did not result in superior objective hair-growth outcomes compared with minoxidil alone. Although patient satisfaction was higher among patients receiving adjunctive cetirizine, this finding may be attributable to factors other than a direct pharmacologic effect. Further double-blind, vehicle-controlled studies with larger sample sizes are warranted to clarify the role of topical cetirizine in the management of AGA.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"15 1","pages":"32"},"PeriodicalIF":0.7,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13619102/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149074976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacist-led Chemotherapy Counseling: Impact on Hospital Admissions, Patient Satisfaction, and Cost Avoidance - A Prospective Pre-post Quality Improvement Study. 药剂师主导的化疗咨询:对住院率、患者满意度和成本规避的影响——一项前瞻性的前后质量改进研究。
IF 0.7
Journal of Research in Pharmacy Practice Pub Date : 2026-09-04 eCollection Date: 2026-01-01 DOI: 10.4103/jrpp.jrpp_24_26
Abdulmohsen Assiri, Isra Abu Median, Khalid Alshahrani, Mohammed Asiri, Osama Alsaeed, Ali Asiri, Mona Abashar, Majid Ali, Aseel Alsraeya
{"title":"Pharmacist-led Chemotherapy Counseling: Impact on Hospital Admissions, Patient Satisfaction, and Cost Avoidance - A Prospective Pre-post Quality Improvement Study.","authors":"Abdulmohsen Assiri, Isra Abu Median, Khalid Alshahrani, Mohammed Asiri, Osama Alsaeed, Ali Asiri, Mona Abashar, Majid Ali, Aseel Alsraeya","doi":"10.4103/jrpp.jrpp_24_26","DOIUrl":"10.4103/jrpp.jrpp_24_26","url":null,"abstract":"<p><strong>Objective: </strong>This study evaluated the impact of structured clinical pharmacist-led counseling on hospital admissions due to chemotherapy side effects, patient satisfaction, and cost avoidance in patients receiving intravenous chemotherapy.</p><p><strong>Methods: </strong>A prospective pre-post quality improvement study was conducted at a tertiary care center in Saudi Arabia. The preintervention cohort (October 2024-February 2025, <i>n</i> = 118) received standard care; the postintervention cohort (April-August 2025, <i>n</i> = 135) received structured 30-min pharmacist-led counseling covering regimen-specific education, anticipatory guidance on toxicity, self-management strategies, red-flag symptom recognition, and monitoring protocols. The primary outcome was the hospital admission rate due to chemotherapy-related side effects. Secondary outcomes included side effect-specific admissions, patient satisfaction, and economic impact.</p><p><strong>Findings: </strong>The intervention achieved a 34.4% relative reduction in admission rates (13.56%-8.89%; <i>P</i> = 0.02; number needed to treat = 22). Complete elimination of admissions for gastrointestinal toxicities and 38.8% reduction in febrile neutropenia admissions were observed. Patient satisfaction reached 94.4%, with 97.2% service coverage. Net cost savings totaled $38,850 over 5 months (ROI: 747%), with febrile neutropenia prevention accounting for 76.6% of savings.</p><p><strong>Conclusion: </strong>Structured pharmacist-led counseling significantly reduced chemotherapy-related hospital admissions, achieved exceptional patient satisfaction, and demonstrated strong economic value, supporting its integration as standard supportive care in oncology practice.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"15 1","pages":"33"},"PeriodicalIF":0.7,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13619101/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149074960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prescription Completeness and Selected Prescribing Indicators in Rural Vietnamese Primary Care: An Uncontrolled Before-and-After Study of a Multifaceted E-prescribing Quality Improvement Intervention. 越南农村初级保健处方完整性和选定处方指标:一项多方面电子处方质量改善干预的非受控前后研究。
IF 0.7
Journal of Research in Pharmacy Practice Pub Date : 2026-09-04 eCollection Date: 2026-01-01 DOI: 10.4103/jrpp.jrpp_48_26
Hieu Tri Bui, Tu Thi Cam Le, Duyen Thi Nhan Le, Thang Nguyen
{"title":"Prescription Completeness and Selected Prescribing Indicators in Rural Vietnamese Primary Care: An Uncontrolled Before-and-After Study of a Multifaceted E-prescribing Quality Improvement Intervention.","authors":"Hieu Tri Bui, Tu Thi Cam Le, Duyen Thi Nhan Le, Thang Nguyen","doi":"10.4103/jrpp.jrpp_48_26","DOIUrl":"10.4103/jrpp.jrpp_48_26","url":null,"abstract":"<p><strong>Objective: </strong>The objective of this study was to assess whether a district-led multifaceted e-prescribing quality-improvement intervention improved outpatient prescription completeness and selected prescribing indicators in rural Vietnamese primary care.</p><p><strong>Methods: </strong>In this uncontrolled before-and-after study, 1000 health-insurance outpatient e-prescriptions were sampled before the intervention (September-November 2022) and 1000 after it (March-May 2023) from nine public primary healthcare facilities using the Health Information System of Vietnam Posts and Telecommunications (HIS-VNPT; locally recorded as VNPT-HIS). The intervention (December 2022-February 2023) combined prescriber education, drug-information support, audit-feedback, pharmacist-prescriber cross-checking, and administrative reminders. The primary outcome was complete key dosing-instruction documentation. Secondary outcomes were other mandatory completeness fields and selected the World Health Organization/International Network for Rational Use of Drugs prescribing indicators.</p><p><strong>Findings: </strong>Full address documentation remained low (31/1000 [3.1%] vs. 29/1000 [2.9%]; <i>P</i> = 0.79). Complete key dosing instructions increased from 956/1000 (95.6%) to 974/1000 (97.4%; <i>P</i> = 0.03). Mean medicines per prescription did not change significantly (4.08 ± 1.535 vs. 4.20 ± 1.348; <i>P</i> = 0.07), and all medicines were prescribed by international nonproprietary name. Antibiotic prescribing increased from 335/1000 (33.5%) to 447/1000 (44.7%; <i>P</i> < 0.001), vitamin prescribing from 136/1000 (13.6%) to 190/1000 (19.0%; <i>P</i> = 0.001), and essential-medicine use changed only slightly (1480/4078 [36.3%] vs. 1568/4197 [37.4%]; <i>P</i> = 0.31).</p><p><strong>Conclusion: </strong>E-prescribing may provide an infrastructure for quality improvement but requires clinical decision support and pharmacy review.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"15 1","pages":"35"},"PeriodicalIF":0.7,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13619103/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149074955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Navigating Therapeutic Frontiers: A Meta-review and Meta-analysis of COVID-19 Treatment Options. 导航治疗前沿:COVID-19治疗方案的荟萃回顾和荟萃分析。
IF 0.7
Journal of Research in Pharmacy Practice Pub Date : 2026-08-28 eCollection Date: 2026-01-01 DOI: 10.4103/jrpp.jrpp_70_25
Sarah Mousavi, Mohsen Bigharaz Ardekani, Awat Feizi
{"title":"Navigating Therapeutic Frontiers: A Meta-review and Meta-analysis of COVID-19 Treatment Options.","authors":"Sarah Mousavi, Mohsen Bigharaz Ardekani, Awat Feizi","doi":"10.4103/jrpp.jrpp_70_25","DOIUrl":"10.4103/jrpp.jrpp_70_25","url":null,"abstract":"<p><p>To assess the efficacy and safety of each therapeutic options in the treatment of COVID-19 by assessing the evidence from existing systematic reviews and meta-analyses, and to carry out an umbrella meta-analysis of all meta-analysis studies to assess the efficacy of each drug. A comprehensive search was carried out in electronic databases for systematic reviews and meta-analyses which compared the efficacy and/or safety of therapeutic options in the treatment of COVID-19. Findings from the reviews were synthesized using tables and forest plots and the pooled estimate of effect size using the DerSimonian and Laird method was used for the updated meta-analysis. The main outcome was mortality. 285 reviews with 152 meta-analyses were included, The analysis of systematic reviews contents indicated that most reviewed drugs were as follows: chroquine/hydroxychloroquine (<i>n</i> = 48), tocilizumab (<i>n</i> = 39), remdesivir (<i>n</i> = 25), corticosteroids (<i>n</i> = 25), JAK inhibitors (<i>n</i> = 12), colchicine (<i>n</i> = 11), ivermectin (<i>n</i> = 8), anakinra (<i>n</i> = 7), favipravir (<i>n</i> = 7), lopinavir/ritonavir (<i>n</i> = 6), ACEI/ARB (<i>n</i> = 6), azithromycin (<i>n</i> = 4), sofosbuvir (<i>n</i> = 4), and Vitamin D (<i>n</i> = 4). Findings from the included reviews suggested that tocilizumab, remdesivir, corticosteroids, JAKI, anakinra, colchicine, ivermectin, and sofosbuvir decreased the rate of mortality significantly in those taking the drugs; otherwise hydroxylchroquine increased the risk of mortality significantly, while Lopinavir/Ritonavir had no benefit and ACEI and azithromycin decreased mortality rate not significantly. lower requirement for mechanical ventilation and intensive care unit admission and a shorter hospital length of stay was observed with the tocilizumab, JAKIs, anakinra, corticosteroids and sofosbuvir Only one third of the included reviews had 70% quality based on the AMSTAR scale assessment. The results of this study have the potential to be a useful tool for the translation of health evidence and for designing the decision support systems for evidence synthesis.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"15 1","pages":"29"},"PeriodicalIF":0.7,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13570699/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148956036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of an Oral Melatonin Suspension in Idiopathic Nocturnal Irritability among Infants Older than 6 Months: A Randomized, Single-blind, Quasi-experimental Trial. 口服褪黑素悬浮液对6个月以上婴儿特发性夜间易怒的疗效:一项随机、单盲、准实验试验
IF 0.7
Journal of Research in Pharmacy Practice Pub Date : 2026-08-28 eCollection Date: 2026-01-01 DOI: 10.4103/jrpp.jrpp_115_25
Elham Safdarian, Hossein Saneian, Majid Khademian, Erfaneh Ghassami, Farnaz Ebrahimi, Sayed Ahmad Sajjadi-Sureshjaani, Ali Mohammad Sabzghabaee
{"title":"Efficacy of an Oral Melatonin Suspension in Idiopathic Nocturnal Irritability among Infants Older than 6 Months: A Randomized, Single-blind, Quasi-experimental Trial.","authors":"Elham Safdarian, Hossein Saneian, Majid Khademian, Erfaneh Ghassami, Farnaz Ebrahimi, Sayed Ahmad Sajjadi-Sureshjaani, Ali Mohammad Sabzghabaee","doi":"10.4103/jrpp.jrpp_115_25","DOIUrl":"10.4103/jrpp.jrpp_115_25","url":null,"abstract":"<p><strong>Objective: </strong>Excessive or frequent night waking in infants can cause significant parental distress, maternal fatigue, family dysfunction, and increased risk of depression and anxiety. Melatonin, a hormone secreted in response to darkness, regulates the sleep-wake cycle. Infants with sleep difficulties may have low melatonin levels; therefore, melatonin supplementation may help improve sleep. This study evaluated the efficacy of an oral melatonin suspension in infants with idiopathic nocturnal irritability.</p><p><strong>Methods: </strong>In this randomized, single-blind quasi-experimental clinical trial, infants aged 6-24 months with idiopathic nocturnal restlessness were assigned to receive either oral melatonin (0.1 mg/kg nightly) or a matching placebo for 14 days. Sleep parameters were recorded by parents at baseline and reassessed after treatment. Infants with organic causes of restlessness, sedative medication use, hypersensitivity, or poor adherence were excluded. Data were analyzed using appropriate statistical tests with a significance level of <i>P</i> < 0.05.</p><p><strong>Findings: </strong>Sixty-seven infants were enrolled; 60 completed the study (30 melatonin and 30 placebo). After 14 days, the melatonin group showed significant reductions in nocturnal awakenings, sleep onset latency, and total nocturnal wakefulness, along with significant increases in longest continuous sleep duration and total sleep time. No significant changes occurred in the placebo group.</p><p><strong>Conclusion: </strong>Melatonin at 0.1 mg/kg appears to be effective and safe as an adjunctive therapy for idiopathic nocturnal restlessness in infants. Further studies with larger samples and longer follow-up are recommended.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"15 1","pages":"26"},"PeriodicalIF":0.7,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13570694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148956027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Disease Course, Outcomes, and Complications in Pregnant and Breastfeeding Women with Multiple Sclerosis Treated with Rituximab or Ocrelizumab: A Narrative Review. 利妥昔单抗或奥克雷单抗治疗多发性硬化症孕妇和哺乳期妇女的病程、结局和并发症:一项叙述性综述
IF 0.7
Journal of Research in Pharmacy Practice Pub Date : 2026-08-28 eCollection Date: 2026-01-01 DOI: 10.4103/jrpp.jrpp_40_26
Fereshteh Ashtari, Mahnaz Momenzadeh
{"title":"Disease Course, Outcomes, and Complications in Pregnant and Breastfeeding Women with Multiple Sclerosis Treated with Rituximab or Ocrelizumab: A Narrative Review.","authors":"Fereshteh Ashtari, Mahnaz Momenzadeh","doi":"10.4103/jrpp.jrpp_40_26","DOIUrl":"10.4103/jrpp.jrpp_40_26","url":null,"abstract":"<p><p>Multiple sclerosis (MS) predominantly affects women of childbearing age, and decision-making regarding disease-modifying therapies during pregnancy and lactation, particularly for highly effective anti-CD20 therapies such as rituximab and ocrelizumab, remains challenging. This review aims to synthesize available evidence on the course of MS, pregnancy, and neonatal outcomes, complications, and safety considerations in pregnant and breastfeeding women with MS exposed to rituximab or ocrelizumab. This structured narrative review was conducted in accordance with the PRISMA reporting framework. A systematic search of major scientific databases was performed for studies published between 2000 and 2026. Included study designs comprised cohorts, registries, case series, case reports, and systematic reviews. Data were extracted based on exposure type (preconception, during pregnancy, postpartum, and during breastfeeding) and key outcomes (relapse and disease activity, live birth, miscarriage, preterm delivery, congenital anomalies, infections, and neonatal immune parameters) and were narratively synthesized. The body of evidence indicates that exposure to rituximab or ocrelizumab, particularly when treatment was administered prior to pregnancy and conception occurred at an interval from the last dose, is often associated with better disease stability during pregnancy and a reduced risk of postpartum relapse. Most reports have not identified a consistent pattern of increased major congenital anomalies, and pregnancy outcomes have generally fallen within expected ranges. The most important neonatal consideration is transient B-cell lymphopenia in some exposures occurring close to late pregnancy; this finding has usually been reported as reversible and requires attention to the timing of live vaccinations. During breastfeeding, existing evidence supports minimal drug transfer into breast milk and the absence of clinically meaningful adverse outcomes in infants. Current evidence suggests that rituximab and ocrelizumab may be considered as strategies for disease control around pregnancy and in the postpartum period in women with active MS. However, decision-making should be individualized, based on disease severity, timing of exposure, maternal benefit, and neonatal monitoring considerations. Prospective studies and expanded pregnancy registries are needed to better evaluate long-term maternal and infant outcomes.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"15 1","pages":"31"},"PeriodicalIF":0.7,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13570691/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148955995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书